caduet: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pharmacia	CADUET	amlodipine besylate; atorvastatin calcium	TABLET;ORAL	021540	NDA	Pfizer Laboratories Div Pfizer Inc	0069-2260-30	30 TABLET, FILM COATED in 1 BOTTLE (0069-2260-30)	2004-01-30
Pharmacia	CADUET	amlodipine besylate; atorvastatin calcium	TABLET;ORAL	021540	NDA	Pfizer Laboratories Div Pfizer Inc	0069-6180-30	30 TABLET, FILM COATED in 1 BOTTLE (0069-6180-30)	2022-08-31
Pharmacia	CADUET	amlodipine besylate; atorvastatin calcium	TABLET;ORAL	021540	NDA	Pfizer Laboratories Div Pfizer Inc	0069-6323-30	30 TABLET, FILM COATED in 1 BOTTLE (0069-6323-30)	2022-08-31
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 3, 2025

Introduction

CADUET is a prescription medication primarily indicated for treating hypertension and angina pectoris. It combines two active ingredients: amlodipine besylate, a calcium channel blocker, and atorvastatin calcium, a statin used to lower cholesterol. As a combination therapy, CADUET's manufacturing and supply chain involve multiple stakeholders spanning raw material providers, formulation specialists, and finished product manufacturers. Ensuring the security and reliability of these suppliers is essential for maintaining drug availability, regulatory compliance, and market competitiveness.

This comprehensive analysis elucidates the key suppliers involved in CADUET's production, critical raw materials, manufacturing hubs, and the associated geopolitical and regulatory considerations affecting the supply chain.

Active Pharmaceutical Ingredient (API) Suppliers

Amlodipine Besylate Suppliers

Amlodipine besylate is the antihypertensive component of CADUET, requiring high-purity API sources:

Hetero Labs Ltd. (India): A prominent API manufacturer, Hetero supplies amlodipine to major pharmaceutical firms globally, leveraging its Good Manufacturing Practice (GMP) certification to meet international standards. India remains a dominant source, owing to cost advantages and robust pharmacopoeia compliance.
Mitsubishi Tanabe Pharma Corporation (Japan): Known for high-quality APIs, Mitsubishi supplies premium amlodipine besylate with rigorous quality controls, often catering to regulated markets like Japan, Europe, and the US.
Novartis (Switzerland): While primarily a drug manufacturer, Novartis also supplies certain APIs through its global manufacturing network, including amlodipine, especially for formulations targeted at European markets.
Generic and Contract Manufacturing Organizations (CMOs): Several Indian and Chinese firms, such as Aurobindo Pharma, Cipla, and Zhejiang Huahai Pharmaceutical, are substantial API providers, often supplying low-cost, high-quality amlodipine to global markets.

Atorvastatin Calcium Suppliers

As the cholesterol-lowering agent, atorvastatin's supply chain is similarly global:

Serum Institute of India: A major supplier of atorvastatin, providing cost-effective APIs for generic markets globally.
Medsen Pharma (China): A key Chinese API producer supplying atorvastatin with comprehensive GMP and quality certifications for export.
Sun Pharmaceutical Industries Ltd. (India): Offers atorvastatin APIs with certifications suitable for regulated markets, emphasizing compliance and batch consistency.
Pfizer (USA): Although Pfizer no longer manufactures atorvastatin after patent expiry, it historically supplied the API, and some licensed manufacturers continue to produce under Pfizer's specifications.

Formulation and Finished Product Manufacturers

Finishing CADUET involves blending APIs into final dosage forms, a process primarily undertaken by pharmaceutical contract manufacturers:

Novartis Pharmaceuticals (US & Switzerland): Original manufacturer of CADUET, controlling the supply chain from formulation to distribution.
Generic Manufacturers: Several regional pharmaceutical companies, such as TEVA Pharmaceuticals, Mylan, and Sun Pharmaceutical Industries, produce generic CADUET formulations, sourcing APIs from the aforementioned suppliers.
Contract Manufacturing Organizations (CMOs): These entities specialize in formulation and packaging. Examples include Catalent, Patheon, and Jubilant Life Sciences, which operate manufacturing plants aligned with Good Manufacturing Practices (GMP). They often source APIs from global suppliers and provide scalable production capacity to meet market demand.

Raw Material and Packaging Material Suppliers

Critical ancillary materials include excipients, binders, and packaging:

Excipients: Suppliers such as DuPont Nutrition & Health, Ashland, and BASF provide pharmaceutical-grade excipients compliant with pharmacopeia standards.
Packaging: Suppliers like Gerresheimer, West Pharmaceutical Services, and Schott AG supply blister packs, bottles, and labels. Their capacities ensure secure packaging, tamper-evidence, and regulatory compliance.

Regional and Regulatory Dynamics

The supply chain for CADUET is heavily influenced by geopolitical factors and regulatory standards:

India and China: The primary global sources for APIs, benefiting from cost efficiencies and manufacturing scale. However, recent trade tensions and regulatory shifts, such as US FDA crackdowns on API manufacturing facilities in India and China, pose supply disruption risks.
US and European Regulatory Bodies: Require stringent quality and GMP certifications, influencing supplier qualification processes. Suppliers must maintain compliance with the FDA, EMA, and other agencies, which adds compliance costs but ensures high standards.
Supply Chain Resilience: The COVID-19 pandemic highlighted vulnerabilities in API sourcing and manufacturing continuity. Many companies now diversify suppliers geographically and strategically stockpile APIs to mitigate risks.

Key Players in CADUET Supply Chain

Segment	Major Suppliers/Manufacturers	Regions	Notable Attributes
Amlodipine Besylate API	Hetero Labs, Mitsubishi Tanabe, Aurobindo Pharma	India, Japan	High-volume, cost-effective, GMP-compliant
Atorvastatin API	Serum Institute, Medsen Pharma, Sun Pharma	India, China	Economical, regulated market supply
Formulation & Packaging	Novartis, TEVA, Catalent	US, Europe, India	Quality assurance, scalable manufacturing
Ancillary Materials	BASF, Ashland, Gerresheimer	Global	Quality excipients, packaging solutions

Regulatory and Supply Chain Challenges

Supply Disruptions: API manufacturing concentration in India and China introduces geopolitical risks; trade restrictions, factory closures, or quality issues could impact supply continuity.
Quality Assurance: Increasing regulatory scrutiny necessitates rigorous supplier qualification and batch validation; non-compliance can lead to delays and regulatory penalties.
Cost Dynamics: Fluctuations in raw material costs, exchange rates, and tariffs influence procurement strategies and pricing of CADUET formulations.
Supply Chain Diversification: Leading manufacturers are increasingly adopting dual sourcing and regional manufacturing hubs to mitigate risks and ensure regulatory compliance.

Strategic Implications for Stakeholders

Pharmaceutical Companies: Should prioritize robust supplier qualification processes, diversify sourcing, and monitor geopolitical developments.
Manufacturers and Distributors: Need to build inventory buffers and establish strong contractual relationships with API suppliers, emphasizing quality and supply security.
Regulatory Agencies: Require transparent reporting of supply chain changes and support initiatives for manufacturing resilience.
Investors and Business Analysts: Must evaluate geopolitical, regulatory, and supplier-specific risks when assessing market stability and growth trajectory for CADUET.

Key Takeaways

The supply of CADUET rests on a complex, globally dispersed network of high-quality API manufacturers, predominantly in India and China, supplemented by international players with rigorous regulatory standards.
Disruptions in raw material supply, regulatory changes, or geopolitical tensions could significantly impact product availability.
Diversification of supplier portfolios and regional manufacturing hubs enhance supply resilience.
Ensuring regulatory compliance across the supply chain remains paramount, involving substantial quality assurance investments.
The strategic sourcing of APIs and formulation inputs will influence pricing, market access, and long-term sustainability of CADUET supply chains.

FAQs

1. Who are the primary API suppliers for amlodipine besylate?
Major API producers include Indian pharmaceutical giants like Aurobindo Pharma, Hetero Labs, and Chinese firms such as Zhejiang Huahai Pharmaceutical, all offering high-quality amlodipine besylate compliant with international GMP standards.

2. Are there risks associated with relying heavily on Indian and Chinese suppliers?
Yes. Geopolitical tensions, trade restrictions, and manufacturing quality issues can pose supply risks. Diversifying sourcing and establishing regional manufacturing hubs mitigate these vulnerabilities.

3. How does regulatory oversight impact API sourcing for CADUET?
Stringent approval and inspection processes by agencies like the US FDA and EMA require suppliers to maintain high standards. Non-compliance can lead to manufacturing halts, forced recalls, or import bans.

4. What role do contract manufacturers play in CADUET’s supply chain?
They handle formulation, packaging, and distribution, sourcing APIs from verified suppliers. Their capacity and quality controls influence product availability and compliance.

5. How might future trends affect CADUET's supply chain?
Increasing regulatory scrutiny, geopolitical shifts, and efforts toward supply chain diversification will shape procurement strategies, emphasizing resilience and quality assurance.

Sources:

[1] U.S. Food & Drug Administration (FDA). API Certification and Inspection Reports.
[2] European Medicines Agency (EMA). Pharmaceutical Manufacturing Standards.
[3] Indian Pharmaceutical Alliance. API Production and Export Data.
[4] Chinese Pharmacopoeia and API manufacturing policies.
[5] Industry Reports on API Market Dynamics and Supply Chain Resilience.

Suppliers and packagers for caduet

caduet

Suppliers for the Pharmaceutical Drug: CADUET